BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1242 related articles for article (PubMed ID: 11095431)

  • 1. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Pastor CL; Griffin-Korf ML; Aloi JA; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 1998 Feb; 83(2):582-90. PubMed ID: 9467578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM; Randolph JF; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
    Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal effects of flutamide in young women with polycystic ovary syndrome.
    De Leo V; Lanzetta D; D'Antona D; la Marca A; Morgante G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):99-102. PubMed ID: 9435423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids.
    Eagleson CA; Bellows AB; Hu K; Gingrich MB; Marshall JC
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5158-62. PubMed ID: 14602743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
    Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
    Hayes FJ; Taylor AE; Martin KA; Hall JE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of androgen blockade on granulosa cell estradiol production after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome.
    Mehta RV; Malcom PJ; Chang RJ
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3503-6. PubMed ID: 16804036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
    Blank SK; McCartney CR; Helm KD; Marshall JC
    Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovulatory effects of flutamide in the polycystic ovary syndrome.
    Paradisi R; Fabbri R; Battaglia C; Venturoli S
    Gynecol Endocrinol; 2013 Apr; 29(4):391-5. PubMed ID: 23327685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.